Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,253 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo First Clear all
Completed Not applicable Interventional Results available

Circadian Effects of Escitalopram

NCT01214044
View directory record Official record
Conditions
Depression
Interventions
placebo/escitalopram
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 18, 2026, 3:51 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

NCT07142707
View directory record Official record
Conditions
Obesity
Interventions
MBX 4291, Placebo
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Doral, Florida • Lexington, Kentucky • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

NCT01490632
View directory record Official record
Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Interventions
Placebo, Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 18, 2026, 3:51 PM EDT
Withdrawn Phase 2 Interventional

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

NCT05974293
View directory record Official record
Conditions
NMO Spectrum Disorder, Spasticity, Muscle
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Michael, Levy M.D.,Ph.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

NCT02963909
View directory record Official record
Conditions
Zika Virus Infection
Interventions
IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 18, 2026, 3:51 PM EDT
Not listed Phase 2 Interventional

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

NCT02771509
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ANG-3777, Placebo
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function

NCT05008549
View directory record Official record
Conditions
Attention, Mood
Interventions
Cranberry Juice Product
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

NCT00302458
View directory record Official record
Conditions
Healthy
Interventions
OROS-Methylphenidate, Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
View directory record Official record
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 18, 2026, 3:51 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

NCT00099320
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 75 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Topiramate in Adolescents With Severe Obesity

NCT01859013
View directory record Official record
Conditions
Obesity, Morbid, Obesity, Weight Loss
Interventions
Topiramate, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 3:51 PM EDT
Withdrawn Phase 2 Interventional

A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia

NCT05171920
View directory record Official record
Conditions
Pneumonia
Interventions
Auxora, Placebo
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Saint Paul, Minnesota • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
ORT247, Placebo
Drug
Lead sponsor
Orthogonal Neuroscience Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 4 Interventional

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease

NCT01014078
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Azithromycin Ophthalmic Solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 18, 2026, 3:51 PM EDT
Not listed Phase 3 Interventional

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00454168
View directory record Official record
Conditions
Leukemia
Interventions
PR1 leukemia peptide vaccine, sargramostim, placebo
Biological · Other
Lead sponsor
The Vaccine Company
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 18, 2026, 3:51 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 18, 2026, 3:51 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

NCT05344989
View directory record Official record
Conditions
Healthy Volunteers, Tauopathies, Alzheimer Disease
Interventions
APNmAb005, Placebo
Drug
Lead sponsor
APRINOIA Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

NCT00894543
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Oakland, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

NCT04583735
View directory record Official record
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 18, 2026, 3:51 PM EDT
Completed Phase 1 Interventional

Psilocybin for the Treatment of Migraine Headache

NCT03341689
View directory record Official record
Conditions
Migraine Headache
Interventions
High Dose Psilocybin, Low Dose Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 18, 2026, 3:51 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.

NCT03067168
View directory record Official record
Conditions
Post Operative Pain
Interventions
Bupivacaine, normal saline 0.9%
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 18, 2026, 3:51 PM EDT
Recruiting Phase 2 Interventional

Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

NCT06226610
View directory record Official record
Conditions
Pruritis
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Akron Children's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 18, 2026, 3:51 PM EDT